EPHA2 and breast carcinoma: Moreover, constitutively present pS-EphA2 in MDA-MB-231 human breast cancer cells harbouring KRAS and BRAF mutations and Panc-1 human pancreatic cancer cells carrying KRAS mutation was also resistant to PI3K inhibition (Fig. 2c).